Coronary Heart Disease. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: saffron capsule, 100 mg, twice daily
(Iranian saffron powder will be provided in capsule form). Intervention 2: placebo, twice daily.
Treatment - Drugs
Placebo
saffron capsule, 100 mg, twice daily
(Iranian saffron powder will be provided in capsule form)
Sponsors
Vice chancellor for research, Tabriz University of Medical Sciences, Nutrition Research Center
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria ; people aged 30 to 60 years (both sexes) ; Angiographic diagnosis of atherosclerosis by a physician, coronary vessels occluded between 30 and 70% with medical follow-up ; No change in medical treatment approach from 2 months prior to the study if possible ; Having not taken any anti-inflammatory and antioxidant supplements for at least 1 month before the start of the study ; willingness to cooperate and sign the informed consent form after being informed of the objectives and method of study. Exclusion criteria ; chronic diseases such as hepatic and renal conditions ; infectious diseases, cancer, allergies and diseases with immunologic pathology ; Use of immunosuppressive drugs (corticosteroids) ; Hematologic disease ; Pregnancy and lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MiR-21 plasma levels gene expression. Timepoint: Pre-intervention and six weeks after the end of intervention. Method of measurement: PCR.;Biochemical factors, Lipid and glucose parameters. Timepoint: Pre-intervention and six weeks after the end of intervention. Method of measurement: Milligrams Per Deciliter.;Quality of life. Timepoint: Pre-intervention and six weeks after the end of intervention. Method of measurement: MacNew questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometric indices. Timepoint: Pre-intervention and six weeks after the end of intervention. Method of measurement: measurements of height, waist and hip circumference with tape measure , weight with Seca scale.;Appetite levels. Timepoint: Pre-intervention and six weeks after the end of intervention. Method of measurement: visual analogue scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShonaz Ahmadi Khatir
Faculty of Nutrition, Tabriz University of Medical Sciences
Outcome results
None listed